Please provide your email address to receive an email when new articles are posted on . INDIANAPOLIS — APX3330, an investigational oral treatment for diabetic retinopathy, reduced the development of ...
Weight loss medications Mounjaro and Zepbound, which contain the active ingredient tirzepatide, may lower the risk of ...
Please provide your email address to receive an email when new articles are posted on . APX3330 is an oral, small-molecule Ref-1 inhibitor being developed for treating diabetic retinopathy. It reduced ...
STOCKHOLM — At the American Society of Retina Specialists (ASRS) 2024 Annual Meeting, researchers discussed how insights into potential risk factors and new treatments could improve outcomes for ...
Company advances Phase 3 AXPAXLI programs, with SOL-1 Week 52 data presentation set for February 2026 and SOL-R topline expected in Q1 2027.
Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology-focused biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, today announces clinical data ...
For patients with type 2 diabetes mellitus, most eyes have no worsening of diabetic retinopathy (DR) after initiation of semaglutide, according to a study presented at the annual meeting of the ...
STOCKHOLM -- The sodium glucose co-transporter 2 (SGLT2) class of diabetes medications may offer more protection against diabetic retinopathy as compared with other hypoglycemic agents, an analysis of ...
LONDON – Long-established, but often forgotten, primary care tools, including the swinging light test and the lipid-lowering drug fenofibrate, may help detect early worsening of diabetic retinopathy ...
Clinical Trials Arena on MSN
Breye Therapeutics’ oral retinopathy drug shows early improvement in disease activity
Breye is advancing danegaptide to Phase II trials after the drug showed signs of improving disease activity in a Phase Ib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results